#ASH24: Treatments for newly diagnosed AML

To update you on the exciting content presented at the 66th ASH Annual Meeting and Exposition, December 7–10, 2024, San Diego, US, we have collated our social media coverage. Catch up here with our live social media relating to treatments for newly diagnosed acute myeloid leukemia.

CONGRESS | #ASH24 | PRESENTATION
Priyanka Mehta @uhbwNHS shares findings from an exploratory post hoc analysis of the UK AML19 trial.
CPX-351 was associated with improved OS and RFS vs FLAG-Ida in younger adult patients with newly diagnosed high-risk AML/MDS and MDS-related gene… pic.twitter.com/vCYdpdwZps

— AML Hub (@AML_Hub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
Ioannis Mantzaris @YannisMantz @MontefioreNYC @EinsteinMed presents results from a phase Ib trial of venetoclax plus 7+3 chemotherapy in newly diagnosed, fit patients aged ≤75 years with AML.
Venetoclax plus 7+3 chemotherapy induction was well… pic.twitter.com/uHDbWVBXO4

— AML Hub (@AML_Hub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
Steven Knapper @cardiffuni shares findings from the UK NCRI AML18 trial.
Daunorubicin/cytarabine plus fractionated gemtuzumab ozogamicin improved survival outcomes vs CPX-351 in older, fit patients with de novo, non-adverse-risk AML.
Follow our… pic.twitter.com/8KgCQBzFlF

— AML Hub (@AML_Hub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION@Dr_AmerZeidan @YaleIMed presents interim phase Ia results from the ongoing KOMET-007 trial.
Ziftomenib combined with 7+3 chemotherapy was well tolerated, with a consistent safety profile across dose levels, and demonstrated evidence of robust… pic.twitter.com/XTNhskD3XH

— AML Hub (@AML_Hub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
Christian Recher @IUCTOncopole shares results from a phase Ib trial of bleximenib in combination with intensive chemotherapy in ND, fit patients with NPM1 mutated or KMT2Ar AML.
Bleximenib plus 7+3 chemotherapy had a manageable safety profile,… pic.twitter.com/rI9hWdTLmK

— AML Hub (@AML_Hub) December 7, 2024

CONGRESS | #ASH24 | PRESENTATION
Chong Chyn Chua @MonashUni @MonashHealth shares findings from the Phase II ALLG AMLM25 INTERVENE trial of LDAC+Ven+midostaurin as a sequential doublet strategy (n=79), vs LDAC+Ven (n=41), in patients with ND AML aged ≥60 yrs, unfit for IC.
The… pic.twitter.com/bxvRzxgm3t

— AML Hub (@AML_Hub) December 8, 2024

CONGRESS | #ASH24 | PRESENTATION@NicholasShortMD @MDAndersonNews shares long-term findings from a study of patients with ND FLT3m AML treated with HMA+Ven+FLT3i triplet (N = 73).
▪️Efficacy overall was comparable to that seen with doublet therapy, and at median follow-up of 26… pic.twitter.com/phBGL6RdUo

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION
Selina Luger @PennLeukemia @PennCancer @Penn discusses results from the phase II PrECOG 0905 study in patients with ND FLT3m AML, randomized 1:1 to gilteritinib (n = 90) or midostaurin (n = 87) induction.
CRc rate was higher with gilteritinib… pic.twitter.com/xiGdb3Yrio

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | POSTER
Pau Montesinos, @HematoLaFe, presents final results of the phase II QUIWI trial (NCT04107727) comparing standard chemotherapy + quizartinib vs placebo in adult patients with newly diagnosed FLT3-ITD negative AML (N=273). Median EFS was 18.8 months with… pic.twitter.com/2tD70cB5HT

— AML Hub (@AML_Hub) December 8, 2024

CONGRESS | #ASH24 | POSTER
Jennifer Marvin-Peek, @MDAndersonNews, presented results from a pooled analysis of two phase Ib/II trials (NCT03471260 and NCT04774393) investigating frontline triplet regimens containing HMA + VEN + IDH inhibitor in patients with newly diagnosed… pic.twitter.com/UXyYQQz9Vt

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | POSTER@DrGMarconi, @IRSTDinoAmadori, shared findings from the phase II Gimema AML1718 trial (NCT03455504) evaluating venetoclax + fludarabine, idarubicine, and cytarabine (V-FLAI) as induction treatment in patients with non low-risk AML (N=124). At a median… pic.twitter.com/OrwJaFfVet

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER
Rebeca Rodriguez-Veiga, @HospitalLaFe, shared findings from the phase II QUIWI PETHEMA trial (NCT04107727) assessing the correlation of quizartinib efficacy with ELN-risk and gene mutations in patients with FLT3-ITD-negative newly diagnosed AML. 3-year… pic.twitter.com/orkhHtodMz

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Jessica M. Stempel @JMStempel @Yale @YaleHemOnc presents results from the phase II BLAST MRD AML-2 trial.
The addition of pembrolizumab to AZA+VEN did not improve MRD-neg CR/CRi and was associated with a trend for worse OS in patients with AML who… pic.twitter.com/JvDWYQAAYa

— AML Hub (@AML_Hub) December 9, 2024

CONGRESS | #ASH24 | PRESENTATION@DanPollyea, @CUSystem, discussed findings from a prospective, single-arm, phase II trial (NCT03573024) of venetoclax + azacitidine in patients with newly diagnosed AML. The study was stopped at Stage 3 (n=27) as the ORR (67%) did not meet the… pic.twitter.com/8gbhuKugLp

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | PRESENTATION
Jing Lu from the First Affiliated Hospital of Soochow University presented updated results from a phase II b trial (NCT05177731) comparing venetoclax + decitabine (Ven-Dec) vs idarubicin + cytarabine (IA-12) as induction therapy in patients with… pic.twitter.com/q0GvhtwNyM

— AML Hub (@AML_Hub) December 10, 2024

CONGRESS | #ASH24 | POSTER
Uma Borate @beatalleukemia @OSUCCC_James presents findings from the Beat AML Master trial regarding outcomes and survival of older patients with ND AML.
mOS was comparable between patients treated with a non-intensive targeted therapy (n = 407) and… pic.twitter.com/wU796s6SZz

— AML Hub (@AML_Hub) December 10, 2024